Texas 2017 - 85th 1st C.S.

Texas Senate Bill SB26

Caption

Relating to the use of certain controlled substances by women who are pregnant or may become pregnant and the designation of neonatal abstinence syndrome from substance use as a reportable condition.

Impact

If enacted, SB26 would significantly influence state health laws related to maternal and child health, especially in addressing opioid issues. The bill mandates the collection of detailed reports of neonatal abstinence syndrome while ensuring that personally identifiable information is protected. This legislative measure not only aims to track the incidence of NAS for public health surveillance but also emphasizes the necessity for improved knowledge and resources regarding substance use during pregnancy. Furthermore, health practitioners will gain access to a defined set of guidelines for screening, which can potentially lead to better health outcomes for both mothers and their children.

Summary

Senate Bill 26 is aimed at addressing the use of certain controlled substances, particularly opioids, by women who are pregnant or may become pregnant. The bill introduces new provisions for screening and reporting associated with neonatal abstinence syndrome (NAS), which can occur when newborns are exposed to drugs in utero. One of the key components of SB26 is the requirement for healthcare providers to screen pregnant patients for substance use and assess prescription histories to support the health of both the mother and the newborn. This highlights the state's proactive approach to combatting the effects of opioid use during pregnancy.

Contention

The introduction of SB26 may not be without contention. Critics might argue that additional regulations around substance use screenings and reporting could foster an environment of mistrust between healthcare providers and patients. There are concerns that such measures may unintentionally dissuade women from seeking prenatal care due to fear of stigma or punitive actions tied to substance use disclosures. Balancing public health interests against patient autonomy and confidentiality will likely be critical points of debate as the bill proceeds through the legislative process. Ultimately, the success of SB26 will depend on how effectively it addresses these concerns while promoting healthier outcomes for pregnant women and their newborns.

Companion Bills

No companion bills found.

Previously Filed As

TX SB673

Relating to the reporting and investigating certain causes of child abuse or neglect involving a pregnant woman's use of a controlled substance.

TX HB811

Relating to reporting and investigating certain cases of child abuse or neglect involving a pregnant person's use of a controlled substance.

TX HB1958

Relating to maternal mortality and morbidity in this state and Medicaid eligibility of and coverage for certain services provided to pregnant women.

TX HB4642

Relating to offenses involving the manufacture or delivery of certain controlled substances and the enforcement and prevention of those offenses; creating a criminal offense.

TX HB56

Relating to the Medicaid eligibility of certain women following a pregnancy.

TX HB1575

Relating to improving health outcomes for pregnant women under Medicaid and certain other public benefits programs.

TX HB3058

Relating to the provision of certain medical treatment to a pregnant woman by a physician or health care provider.

TX SB73

Relating to the Medicaid eligibility of certain women following a pregnancy.

TX SB124

Relating to the Medicaid eligibility of certain women during and following a pregnancy.

TX HB5298

Relating to a pilot program under which lockable, tamper-evident containers are used by participating pharmacies when dispensing schedule II controlled substances.